Thermo Fisher Scientific last month approved a new base salary for its new president and CEO Marc Casper.
His annual base salary has been raised to $930,000 with a target annual incentive bonus of 115 percent of base salary retroactive to Sept. 15, when the company announced he would be replacing Marijn Dekkers as president and CEO. The actual amount paid as a bonus is between zero and twice the target amount, the company said in a document filed with the US Securities and Exchange Commission.
In his prior position as executive vice president and COO of Thermo Fisher, Casper received a base salary of $739,000. Dekkers' base salary was $1.2 million.
Casper was also granted the option to purchase various amounts of Thermo Fisher's common stock under certain terms, as well as time-based restricted stock units.
The Human Proteome Organization last week announced the election of Catherine Costello as its next president.
She will begin her two-year term on Jan. 1, 2011 when she replaces Young Ki-Paik, the current HUPO president.
Costello is a professor of biochemistry, biophysics, and chemistry at Boston University, where she is also director of the school's Mass Spectrometry Resource and Cardiovascular Proteomics Center.
Also, HUPO announced the election of five new council members. They are Christoph Borchers, director of the Genome British Columbia Proteomics Centre at the University of Victoria, Canada; Hisashi Hirano, vice-director of the Advanced Medical Research Center of Yokohama City University, Japan; Donald Hunt, professor of chemistry and pathology at the University of Virginia; Carol Robinson, professor of chemistry at the University of Oxford, UK; and Michael Siu, director of the Centre for Research in Mass Spectrometry at York University, Canada.
Canadian diagnostics and therapeutics company biOasis last month named Delara Karkan its senior industry scientific advisor.
Karkan is currently senior science advisor to the Office of Science and Risk Management, Health Products and Food branch in Canada, and is advisor to the US Food and Drug Administration's nanotechnology task force. She has served as deputy director in the Biologics and Genomic Therapy Directorate at Health Canada, where she was responsible for the preclinical safety unit.